EU Facial Injectables Market
In 2010, the European market for aesthetic neuromodulators reached $238.8 million. Through 2015, total European sales are expected to rise by 12.8% per year, on average, to $376.9 million. The emergence of new neuromodulator brands for aesthetic use such as Azzalure (Galderma) and Bocouture (Merz Aesthetics) is continuing to reduce the gap between the margins of market leader Allergan and its competitors and has already slowed the annual growth rate of Allergan's neuromodulator revenues in Europe. Through 2015, European sales of dermal fillers are expected to expand by 8.2% per year, on average, from $320.3 million in 2010 to more than $475.6 million in 2015. This reflects both current usage trends and a visible European market recovery from the recession of 2008 to 2009…

Reflecting a deep understanding of the European market/s, business climate/s, economy, health care system/s and consumer preferences, this report provides detailed insight on:

• the unique characteristics of the EU neuromodulator and dermal fillers markets;
• drivers and restraints of each market;
  detailed discussion of the individual country markets (UK, Germany, France, Italy, Spain, Russia, Benelux, Turkey, Austria and others) with regard to injectables;
• estimated EU sales of 5 top neuromodulator sellers and 15 leading dermal filler producers for each year from 2010 to 2015;
• comprehensive analysis of the products and injectable businesses of the top 19 players in the EU;
• discussion of important pipeline products;
• number of practitioners, procedure volume, treatment frequency, treatment fees and total physician procedure fees in the EU for neuromodulators and dermal fillers.